Trial Profile
Impact of neoadjuvant chemotherapy with or without Zometa [zoledronic acid] on occult micrometastases and bone density in women with locally advanced breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2021
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Antineoplastics; Dexamethasone; Docetaxel; Epirubicin; Granulocyte colony-stimulating factors; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer; Bone metastases; Osteoporosis
- Focus Therapeutic Use
- 21 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
- 31 Mar 2010 Results reported in Lancet Oncology.
- 22 Aug 2006 Status change